Research in the cannabinoid field, namely on phytocannabinoids, the endogenous cannabinoids anandamide and 2-arachidonoyl glycerol and their metabolizing and synthetic enzymes, the cannabinoid receptors, and anandamide-like cannabinoid compounds, has expanded tremendously over the last few years. Numerous endocannabinoid-like compounds have been discovered. The Cannabis plant constituent cannabidiol (CBD) was found to exert beneficial effects in many preclinical disease models ranging from epilepsy, cardiovascular disease, inflammation, and autoimmunity to neurodegenerative and kidney diseases and cancer. CBD was recently approved in the United States for the treatment of rare forms of childhood epilepsy. This has triggered the development of many CBD-based products for human use, often with overstated claims regarding their therapeutic effects. In this article, the recently published research on the chemistry and biological effects of plant cannabinoids (specifically CBD), endocannabinoids, certain long-chain fatty acid amides, and the variety of relevant receptors is critically reviewed.

中文翻译：

---

除了四氢大麻酚和内源性大麻素。

在过去几年中，大麻素领域的研究，即植物大麻素，内源性大麻素anandamide和2-arachidonoyl甘油及其代谢和合成酶，大麻素受体和类似anandamide的大麻素化合物，已经得到了极大的发展。已经发现了许多类内源性大麻素化合物。人们发现，大麻植物成分大麻二酚（CBD）在许多临床前疾病模型中发挥有益作用，从癫痫，心血管疾病，炎症和自身免疫到神经退行性疾病，肾脏疾病和癌症。CBD最近在美国被批准用于治疗罕见形式的儿童癫痫病。这触发了许多基于CBD的人类使用产品的开发，这些产品通常声称其治疗效果过高。